What's in OBEcure Ltd.'s pipeline?

OBEcure Ltd. has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with OBEcure Ltd.'s portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/obecure-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

OBEcure Ltd. — Portfolio Competitive Intelligence Brief

OBEcure Ltd. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Betahistine Extended Release formulation	Betahistine Extended Release formulation	marketed	Histamine H1 receptor agonist / H3 receptor antagonist	Histamine H1 receptor, Histamine H3 receptor	Otolaryngology / Neurology

Therapeutic area mix

Otolaryngology / Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for OBEcure Ltd.:

Cite this brief

Drug Landscape (2026). OBEcure Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/obecure-ltd. Accessed 2026-05-15.